AU2010210892A1 - Methods for amplifying Hepatitis C virus nucleic acids - Google Patents
Methods for amplifying Hepatitis C virus nucleic acids Download PDFInfo
- Publication number
- AU2010210892A1 AU2010210892A1 AU2010210892A AU2010210892A AU2010210892A1 AU 2010210892 A1 AU2010210892 A1 AU 2010210892A1 AU 2010210892 A AU2010210892 A AU 2010210892A AU 2010210892 A AU2010210892 A AU 2010210892A AU 2010210892 A1 AU2010210892 A1 AU 2010210892A1
- Authority
- AU
- Australia
- Prior art keywords
- seq
- nucleotide sequence
- nucleotides
- independently
- primer comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 96
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 69
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 69
- 241000711549 Hepacivirus C Species 0.000 title claims description 210
- 150000007523 nucleic acids Chemical class 0.000 title claims description 69
- 239000002773 nucleotide Substances 0.000 claims abstract description 644
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 644
- 230000000295 complement effect Effects 0.000 claims abstract description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 8
- 238000003752 polymerase chain reaction Methods 0.000 claims description 131
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 80
- 238000010839 reverse transcription Methods 0.000 claims description 73
- 108020004414 DNA Proteins 0.000 claims description 24
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 23
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 23
- 108091093088 Amplicon Proteins 0.000 claims description 22
- 230000003321 amplification Effects 0.000 claims description 22
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 22
- 239000011541 reaction mixture Substances 0.000 claims description 18
- 108010002747 Pfu DNA polymerase Proteins 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 238000010367 cloning Methods 0.000 claims description 11
- 230000001580 bacterial effect Effects 0.000 claims description 10
- SKTOEGXJUNJCDC-UHFFFAOYSA-N d(a20) s-oligo Chemical compound C1=NC2=C(N)N=CN=C2N1C(OC1COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)CO)CC1OP(O)(=S)OCC(O1)C(O)CC1N1C(N=CN=C2N)=C2N=C1 SKTOEGXJUNJCDC-UHFFFAOYSA-N 0.000 claims description 10
- 238000007862 touchdown PCR Methods 0.000 claims description 9
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 8
- 238000012163 sequencing technique Methods 0.000 claims description 8
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 claims description 6
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 5
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 5
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 5
- 101710144128 Non-structural protein 2 Proteins 0.000 claims description 5
- 101710199667 Nuclear export protein Proteins 0.000 claims description 5
- 229960003237 betaine Drugs 0.000 claims description 5
- 101800001020 Non-structural protein 4A Proteins 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- 101800001019 Non-structural protein 4B Proteins 0.000 claims description 3
- 101800001014 Non-structural protein 5A Proteins 0.000 claims description 3
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 101710118188 DNA-binding protein HU-alpha Proteins 0.000 claims 2
- 101710144111 Non-structural protein 3 Proteins 0.000 claims 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims 1
- -1 HCV nucleic acid Chemical class 0.000 abstract description 3
- 239000013615 primer Substances 0.000 description 222
- 238000003757 reverse transcription PCR Methods 0.000 description 35
- 239000000523 sample Substances 0.000 description 28
- 210000002381 plasma Anatomy 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 18
- 239000000047 product Substances 0.000 description 15
- 230000035945 sensitivity Effects 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000003556 assay Methods 0.000 description 8
- 108020004635 Complementary DNA Proteins 0.000 description 7
- 102100024058 Flap endonuclease GEN homolog 1 Human genes 0.000 description 7
- 101000833646 Homo sapiens Flap endonuclease GEN homolog 1 Proteins 0.000 description 7
- 238000010804 cDNA synthesis Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 108020000999 Viral RNA Proteins 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 101100519158 Arabidopsis thaliana PCR2 gene Proteins 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 102100034349 Integrase Human genes 0.000 description 4
- 108010076039 Polyproteins Proteins 0.000 description 4
- 238000002123 RNA extraction Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 108010022999 Serine Proteases Proteins 0.000 description 3
- 102000012479 Serine Proteases Human genes 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 241000713838 Avian myeloblastosis virus Species 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 101150102573 PCR1 gene Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101100208307 Acidithiobacillus ferrooxidans (strain ATCC 23270 / DSM 14882 / CIP 104768 / NCIMB 8455) tth gene Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108010019653 Pwo polymerase Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108700010756 Viral Polyproteins Proteins 0.000 description 1
- 108700022715 Viral Proteases Proteins 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 208000020403 chronic hepatitis C virus infection Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 108091069025 single-strand RNA Proteins 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/113—PCR
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Pathology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14608309P | 2009-01-21 | 2009-01-21 | |
| US61/146,083 | 2009-01-21 | ||
| PCT/US2010/021589 WO2010090857A2 (en) | 2009-01-21 | 2010-01-21 | Methods for amplifying hepatitis c virus nucleic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2010210892A1 true AU2010210892A1 (en) | 2011-08-11 |
Family
ID=42334055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010210892A Abandoned AU2010210892A1 (en) | 2009-01-21 | 2010-01-21 | Methods for amplifying Hepatitis C virus nucleic acids |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8679740B2 (enExample) |
| EP (1) | EP2389452A2 (enExample) |
| JP (1) | JP2012515534A (enExample) |
| KR (1) | KR20120101278A (enExample) |
| CN (1) | CN102341506A (enExample) |
| AU (1) | AU2010210892A1 (enExample) |
| CA (1) | CA2749969A1 (enExample) |
| IL (1) | IL214195A0 (enExample) |
| MX (1) | MX2011007693A (enExample) |
| NZ (1) | NZ594155A (enExample) |
| RU (1) | RU2011134857A (enExample) |
| WO (1) | WO2010090857A2 (enExample) |
| ZA (1) | ZA201105349B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX352987B (es) | 2007-10-02 | 2017-12-15 | Theranos Ip Co Llc | Dispositivos modulares de punto de cuidado y usos de los mismos. |
| CA2825196C (en) | 2011-01-21 | 2021-01-05 | Theranos, Inc. | Systems and methods for sample use maximization |
| US9619627B2 (en) | 2011-09-25 | 2017-04-11 | Theranos, Inc. | Systems and methods for collecting and transmitting assay results |
| US9632102B2 (en) | 2011-09-25 | 2017-04-25 | Theranos, Inc. | Systems and methods for multi-purpose analysis |
| US8475739B2 (en) | 2011-09-25 | 2013-07-02 | Theranos, Inc. | Systems and methods for fluid handling |
| US20140170735A1 (en) | 2011-09-25 | 2014-06-19 | Elizabeth A. Holmes | Systems and methods for multi-analysis |
| US9268915B2 (en) | 2011-09-25 | 2016-02-23 | Theranos, Inc. | Systems and methods for diagnosis or treatment |
| US8840838B2 (en) | 2011-09-25 | 2014-09-23 | Theranos, Inc. | Centrifuge configurations |
| US9664702B2 (en) | 2011-09-25 | 2017-05-30 | Theranos, Inc. | Fluid handling apparatus and configurations |
| US9250229B2 (en) | 2011-09-25 | 2016-02-02 | Theranos, Inc. | Systems and methods for multi-analysis |
| US10012664B2 (en) | 2011-09-25 | 2018-07-03 | Theranos Ip Company, Llc | Systems and methods for fluid and component handling |
| US9810704B2 (en) | 2013-02-18 | 2017-11-07 | Theranos, Inc. | Systems and methods for multi-analysis |
| CN105683751B (zh) | 2013-09-06 | 2020-01-17 | 赛拉诺斯知识产权有限责任公司 | 用于接收拭子的装置、系统、方法和套件 |
| BR112016004994A2 (pt) | 2013-09-06 | 2021-05-11 | Theranos Ip Company, Llc | Sistemas e métodos para detectar doenças infecciosas |
| CN106222306A (zh) * | 2016-08-30 | 2016-12-14 | 合肥金域医学检验所有限公司 | 一种hcv病毒ns5a蛋白编码序列突变检测试剂盒 |
| GB201819726D0 (en) * | 2018-12-03 | 2019-01-16 | Diagnostics For The Real World Ltd | HCV detection |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| DE3329892A1 (de) | 1983-08-18 | 1985-03-07 | Köster, Hubert, Prof. Dr., 2000 Hamburg | Verfahren zur herstellung von oligonucleotiden |
| FR2596761B1 (fr) | 1986-04-08 | 1988-05-20 | Commissariat Energie Atomique | Derives de nucleosides et leur utilisation pour la synthese d'oligonucleotides |
| US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
| US5310652A (en) | 1986-08-22 | 1994-05-10 | Hoffman-La Roche Inc. | Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription |
| EP0787807B1 (en) | 1991-08-27 | 2003-05-28 | F. Hoffmann-La Roche Ag | Primers and probes for hepatitis C detection |
| EP0532258A2 (en) * | 1991-09-09 | 1993-03-17 | Immuno Japan Inc. | Oligonucleotides and determination system of HCV genotypes |
| JPH0775585A (ja) * | 1993-06-14 | 1995-03-20 | Immuno Japan:Kk | Ｃ型肝炎ウイルス関連オリゴヌクレオチドならびにｃ型肝炎 ウイルス遺伝子型判定方法 |
| ZA966663B (en) | 1995-08-17 | 1998-02-06 | Genentech Inc | Traf Inhibitors. |
| US6153421A (en) * | 1997-07-18 | 2000-11-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Cloned genomes of infectious hepatitis C viruses and uses thereof |
| WO2002064842A2 (en) * | 2001-02-13 | 2002-08-22 | Children`S Hospital Research Foundation | Quantitative epstein barr virus pcr rapid assay |
| JP3751867B2 (ja) * | 2001-09-18 | 2006-03-01 | 株式会社東芝 | インターフェロンを投与されるべき個体においてインターフェロン療法の有効性を予測する方法、その方法をコンピュータにより実行させるためのプログラム、インターフェロン感受性に関連する多型部位の遺伝子型を検出するための核酸プローブ、およびその核酸プローブを具備する塩基配列検出用チップ |
| AU2003230790A1 (en) * | 2002-04-03 | 2003-10-20 | Smithkline Beecham Corporation | Hepatitis c virus sub-genomic replicons |
| US20040137539A1 (en) * | 2003-01-10 | 2004-07-15 | Bradford Sherry A. | Cancer comprehensive method for identifying cancer protein patterns and determination of cancer treatment strategies |
| WO2004073599A2 (en) | 2003-02-18 | 2004-09-02 | Pfizer Inc. | Inhibitors of hepatitis c virus, compositions and treatments using the same |
| US20050282179A1 (en) | 2003-12-05 | 2005-12-22 | Applera Corporation | Biomarkers for interferon-alpha response in hepatitis C virus infected patients |
| JPWO2006085407A1 (ja) * | 2005-02-09 | 2008-12-18 | 学校法人日本大学 | Ｈｃｖ量に関連する遺伝子のスクリーニング方法 |
| EP2711427A1 (en) * | 2007-04-27 | 2014-03-26 | Advanced Life Science Institute, Inc. | HCV gene |
| JP4213759B2 (ja) * | 2007-08-10 | 2009-01-21 | 株式会社東芝 | 標的核酸の遺伝子型、および変異の判定方法、不溶性支持体に核酸断片を固定化する方法、所望の核酸を精製し、かつ増幅するための方法、並びに遺伝子型アッセイキット |
-
2010
- 2010-01-21 AU AU2010210892A patent/AU2010210892A1/en not_active Abandoned
- 2010-01-21 CN CN2010800098527A patent/CN102341506A/zh active Pending
- 2010-01-21 NZ NZ594155A patent/NZ594155A/xx not_active IP Right Cessation
- 2010-01-21 CA CA2749969A patent/CA2749969A1/en not_active Abandoned
- 2010-01-21 JP JP2011546450A patent/JP2012515534A/ja active Pending
- 2010-01-21 WO PCT/US2010/021589 patent/WO2010090857A2/en not_active Ceased
- 2010-01-21 KR KR1020117019326A patent/KR20120101278A/ko not_active Withdrawn
- 2010-01-21 MX MX2011007693A patent/MX2011007693A/es not_active Application Discontinuation
- 2010-01-21 EP EP10703544A patent/EP2389452A2/en not_active Ceased
- 2010-01-21 RU RU2011134857/10A patent/RU2011134857A/ru not_active Application Discontinuation
-
2011
- 2011-07-19 IL IL214195A patent/IL214195A0/en unknown
- 2011-07-20 ZA ZA2011/05349A patent/ZA201105349B/en unknown
- 2011-07-20 US US13/186,985 patent/US8679740B2/en not_active Expired - Fee Related
-
2014
- 2014-01-28 US US14/165,757 patent/US20140199684A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN102341506A (zh) | 2012-02-01 |
| WO2010090857A2 (en) | 2010-08-12 |
| KR20120101278A (ko) | 2012-09-13 |
| WO2010090857A8 (en) | 2012-06-28 |
| NZ594155A (en) | 2013-02-22 |
| CA2749969A1 (en) | 2010-08-12 |
| US8679740B2 (en) | 2014-03-25 |
| US20140199684A1 (en) | 2014-07-17 |
| WO2010090857A3 (en) | 2010-11-25 |
| IL214195A0 (en) | 2011-08-31 |
| MX2011007693A (es) | 2011-09-27 |
| US20120129155A1 (en) | 2012-05-24 |
| EP2389452A2 (en) | 2011-11-30 |
| ZA201105349B (en) | 2013-10-30 |
| JP2012515534A (ja) | 2012-07-12 |
| RU2011134857A (ru) | 2013-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8679740B2 (en) | Methods for amplifying hepatitis C virus nucleic acids | |
| US8945833B2 (en) | Method for determining drug resistance mutations in any of the non-structural protein regions NS3 to NS5B of hepatitis C virus (HCV) for genotypes 1 to 6 | |
| JP2012515534A5 (enExample) | ||
| KR101501414B1 (ko) | 노로바이러스 검출을 위한 등온증폭 반응용 프라이머 및 이를 이용한 노로바이러스 검출 방법 | |
| AU2008249300A1 (en) | Methods and compositions for identifying and characterizing hepatitis C | |
| JP2019013248A (ja) | Ｈｅｖ核酸を検出するための組成物および方法 | |
| EP2576841B1 (en) | Method for specific detection of classical swine fever virus | |
| EP3126530B1 (en) | Method for specific detection of classical swine fever virus | |
| US7786294B2 (en) | Compositions and methods for amplification and cloning of near full-length viral genome samples | |
| US20040101820A1 (en) | Polynucleotide probe and primer originating in hepatitis e virus of japanese, chips having the same, kits having the same and method of detecting hepatits e virus using the same | |
| US10202659B2 (en) | Primers and methods for detecting human hepatitis C virus (HCV) variants in an isolated sample | |
| HK1163188A (en) | Methods for amplifying hepatitis c virus nucleic acids | |
| EP1721015B1 (en) | Primer and probe design for efficient amplification and detection of hcv 3' non-translating region | |
| JP2011501953A (ja) | Ｈｃｖ遺伝子型タイピングおよび表現型タイピング | |
| CN1270228A (zh) | 用于有效反转录丙型肝炎病毒(hcv)rna的寡核苷酸引物及其使用方法 | |
| WO2000033635A2 (en) | Primer-independent rna synthesis catalyzed by hcv polymerase | |
| HK40056876A (en) | Compositions and method for detecting human parvovirus nucleic acid and for detecting hepatitis a virus nucleic acids | |
| CN113215308B (zh) | 检测人细小病毒核酸和甲型肝炎病毒核酸的组合物和方法 | |
| HK40102397A (en) | Compositions and methods for detecting hev nucleic acid | |
| Zhang et al. | Enhanced protocol for determining the 3′ terminus of hepatitis C virus | |
| WO2020117769A1 (en) | Hcv detection | |
| CN113215308A (zh) | 检测人细小病毒核酸和甲型肝炎病毒核酸的组合物和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |